FDA to Review Pharming’s Application for Ruconest as HAE Swelling Prevention
The U.S. Food and Drug Administration (FDA) has agreed to review Pharming’s application to get Ruconest (conestat alfa) approved for the routine prevention of swelling attacks caused by hereditary angioedema (HAE). The therapy already is approved for the acute treatment of swelling attacks in adults and adolescents with…